Jin H Song

Summary

Affiliation: Medical University of South Carolina
Country: USA

Publications

  1. pmc Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737
    Jin H Song
    Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Res 72:294-303. 2012
  2. pmc The BH3 mimetic ABT-737 induces cancer cell senescence
    Jin H Song
    Department of Biochemistry and Molecular Biology, The Hollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Res 71:506-15. 2011
  3. pmc p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase
    Marina Zemskova
    Department of Cell and Molecular Pharmacology, Hollings Cancer Center, Charleston, SC 29425, USA
    Mol Cancer Res 8:1126-41. 2010
  4. pmc A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma
    Ying Wei Lin
    Department of Pediatrics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
    Blood 115:824-33. 2010
  5. pmc ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis
    Jin H Song
    Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Biol Chem 283:25003-13. 2008
  6. pmc The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling
    Bo Cen
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA The Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
    Mol Cell Biol 34:2517-32. 2014
  7. pmc Regulation of prostate stromal fibroblasts by the PIM1 protein kinase
    Marina Y Zemskova
    Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC 29425, United States The Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, United States Electronic address
    Cell Signal 27:135-46. 2015
  8. pmc Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors
    Shilpak Chatterjee
    Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina
    Cancer Res 74:6048-59. 2014

Collaborators

Detail Information

Publications8

  1. pmc Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737
    Jin H Song
    Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Res 72:294-303. 2012
    ....
  2. pmc The BH3 mimetic ABT-737 induces cancer cell senescence
    Jin H Song
    Department of Biochemistry and Molecular Biology, The Hollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Res 71:506-15. 2011
    ..Thus, in multiple cancer types in which ABT-737 is incapable of causing cell death, ABT-737 may have additional cellular activities that make its use as an anticancer agent highly attractive...
  3. pmc p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase
    Marina Zemskova
    Department of Cell and Molecular Pharmacology, Hollings Cancer Center, Charleston, SC 29425, USA
    Mol Cancer Res 8:1126-41. 2010
    ..Based on these results, PIM1 will have its most profound effects on tumorigenesis in situations where the senescence response is inactivated...
  4. pmc A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma
    Ying Wei Lin
    Department of Pediatrics, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
    Blood 115:824-33. 2010
    ..Our data suggest that inhibition of the Pim protein kinases may be developed as a therapeutic strategy for the treatment of pre-T-LBL...
  5. pmc ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis
    Jin H Song
    Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Biol Chem 283:25003-13. 2008
    ..Combinations of ABT-737 and TRAIL can be exploited therapeutically where antiapoptotic Bcl-2 family members drive tumor cell resistance to current anticancer therapies...
  6. pmc The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling
    Bo Cen
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA The Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
    Mol Cell Biol 34:2517-32. 2014
    ..These results suggest that Pim inhibitors may have an important role in the treatment of patients where MET is driving tumor biology. ..
  7. pmc Regulation of prostate stromal fibroblasts by the PIM1 protein kinase
    Marina Y Zemskova
    Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC 29425, United States The Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, United States Electronic address
    Cell Signal 27:135-46. 2015
    ..Together these results point on PIM1 as a novel factor in regulation of the phenotype and differentiation of fibroblasts in prostate cancer by controlling both the transcription and translation of specific mRNAs. ..
  8. pmc Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors
    Shilpak Chatterjee
    Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina
    Cancer Res 74:6048-59. 2014
    ..Overall, we show that including TGFβ in ex vivo cultures used to program Th17 cells blunts their immunotherapeutic potential and demonstrate how this potential can be more fully realized for adoptive T-cell therapy...